Merck–SciBrunch SPR2015: A $400M Preclinical Bet | Lucid Diligence Brief
This Lucid Diligence Brief examines Merck’s licensing deal for SciBrunch’s…
Lucid Diligence Brief: Fortitude Biomedicines launch with $13M seed
Lucid Diligence Brief: Fortitude Biomedicines launch with $13M seed…
Lucid Diligence Brief: Triana Biomedicines $120M Series B for TRI-611 in ALK+ NSCLC
Lucid Diligence Brief: Triana Biomedicines $120M Series B for TRI-611 in ALK+…
